Spark Therapeutics LLC, Pfizer deal

The companies partnered to develop and commercialize Spark’s SPK-FIX program to treat hemophilia Beta. The bioengineered adeno-associated virus (AAV) vector is expected to enter clinical trials in 1H15. Spark will receive $20 million up front and is eligible for up to $260 million in development and commercialization milestones. Spark is responsible for conducting Phase I/II trials and is eligible to receive double-digit royalties. Pfizer is responsible for pivotal studies, regulatory approvals and commercialization. ...